Cidara Therapeutics Maintains "Buy" Rating Amid New Influenza Data

H.C. Wainwright reiterated its "Buy" rating for Cidara Therapeutics, Inc. (NASDAQ:CDTX), with the stock priced at $98.27 following promising influenza data.CD388, a non-vaccine influenza preventative candidate, showed translational efficacy in the Phase 2b NAVIGATE study, supporting the ongoing Phase 3 ANCHOR trial.Despite a slight decrease in stock price to $97.31, CDTX's market capitalization stands at approximately $2.47 billion, indicating strong investor interest and market position.On October 23, 2025 ...